Orthocell (ASX:OCC)
ASX announcement history & article coverage
Transparent by design.
Announcments by Orthocell (ASX:OCC) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Quarterly Activity Report & Appendix 4C
Orthocell posts record FY2026 revenue of AUD 13.2M with strong US and international growth, robust cash position supports expansion
Orthocell Investor Webinar Details
Orthocell Appoints Thailand Distributor for Remplir
Orthocell appoints MediTime as exclusive Remplir distributor in Thailand's US$84 million nerve repair market
Clinical Outcomes See Expanded Use of Remplir in the Ukraine
Cleansing Notice
Application for quotation of securities - OCC
Cleansing Notice
Application for quotation of securities - OCC
Appendix 3Y - Michael McNulty
Appendix 3Y - John Van Der Wielen
First Sales of Remplir Achieved in US$75m Canadian Market
Orthocell Achieves First Commercial Sales of Remplir™ in Canada, Expands Global Rollout
Compelling 90% Success Rate for Remplir in Real World Study
Orthocell's Remplir™ achieves 90% success rate in nerve repair study, supporting US and EU market growth
Q3 FY26 Investor Presentation
Orthocell posts strong Q3 FY26 growth with US sales momentum and $48M cash runway
Quarterly Activity Report & Appendix 4C
Orthocell posts $3.2M Q1 revenue with US market growth and strong cash reserves
First Surgical Use of Remplir in US Department of Defense
Orthocell completes first Remplir surgical case in U.S. DoD and VA hospitals following approval
OCC Secures Access to 221 U.S. Military Medical Centres
Orthocell gains U.S. Department of Defence and Veterans Affairs approval for Remplir™ nerve repair device
Notification of cessation of securities - OCC
Orthocell Investor Webinar Details